Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1∗07:01

Pharmacogenomics Journal

Volumn 16, Issue 2, 2016, Pages 180-185

  Parham, L R ^a   Briley, L P ^a   Li, L ^a   Shen, J ^a   Newcombe, P J ^b   King, K S ^a   Slater, A J ^a   Dilthey, A ^c   Iqbal, Z ^c   McVean, G ^c   Cox, C J ^b   Nelson, M R ^a   Spraggs, C F ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN; LAPATINIB; LEUKOCYTE ANTIGEN; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; HLA-DRB1*07:01:01 ANTIGEN; QUINAZOLINE DERIVATIVE;

ALLELE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; GENE LOCUS; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERSENSITIVITY; INCIDENCE; LAPATINIB INDUCED LIVER INJURY; LIVER INJURY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BREAST NEOPLASMS; CASE CONTROL STUDY; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; CLINICAL TRIAL; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HYPERBILIRUBINEMIA; INDEL MUTATION; METABOLISM; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ALANINE TRANSAMINASE; ALLELES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HLA-DRB1 CHAINS; HUMANS; HYPERBILIRUBINEMIA; INDEL MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK;

EID: 84929678510     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.40     Document Type: Article

References (26)

1. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010; 11: 973-987
2. Mallal SA, Phillips EJ, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B 5701 screening for hypersensitivity to abacavir. New Engl J Med 2008; 358: 568-579
3. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC et al. Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. New Engl J Med 2011; 364: 1126-1133
4. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe?er I, Floratos A et al. HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819
5. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338-347
6. Kindmark A, Jawaid A, Harbron CG, Barratt BT, Bengtsson OF, Andersson TB et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8: 186-195
7. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42: 711-714
8. Moy B, Rappold E, Williams L, Kelly T, Nicolodi L, Maltzman JD et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol 2009; 27: 1043
9. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS et al. HLA-DQA1 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29: 667-673
10. Spraggs CF, Parham LR, Hunt CM, Dollery CT. Lapatinib-induced liver injury characterized by Class II HLA and Gilbert?s syndrome genotypes. Clin Pharmacol Ther 2012; 91: 647-652
11. Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B et al. Prospective validation of HLA-DRB1 07:01/DQA1 02:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol 2014; 32: 2296-2303
12. Goss PE, Smith IE, O?Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 88-96
13. Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res 2011; 21: 936-939
14. Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRWGS500 Consortiumet al. Integrating mapping-, assembly-nd haplotype-based approaches for calling variants in clinical sequencing applications. Nat Genet 2014; 46: 912-918
15. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 2010; 26: 2069-2070
16. Robinson J, Waller MJ, Fail SC, McWilliam H, Lopez R, Parham P et al. The IMGT/HLA database. Nucleic Acids Res 2009; 37: D1013-D1017
17. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44: 291-296
18. Jia X, Han B, Onengut-Gumuscu S, Chen W-M, Concannon PJ, Rich SS et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013; 8: e64683
19. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249
20. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-1081
21. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 2012; 52: 401-431
22. Dilthey A, Cox C, Iqbal Z, Nelson MR, McVean G. A population reference graph for diploid genome inference. 2014. Available at http://biorxiv.org/content/early/2014/07/08/006973. Last accessed 30 September 2014
23. Zheng X, Shen J, Cox C, Wakefield JC, Ehm MG, Nelson MR et al. HIBAG-HLA genotype imputation with attribute bagging. Pharmacogenomics 2014; 14: 192-200
24. Urban TJ, Goldstein DB. Pharmacogenetics at 50: genomic personalization comes of age. Sci Transl Med 2014; 6: 220ps1
25. Chessman D, Kostenko L, Lethborg D, Purcell AW, Williamson NA, Chen Z et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28: 822-832
26. Monshi M, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ et al. Human Leukocyte Antigen (HLA)-B 57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57: 727-739